Calliditas Therapeutics AB (CALT) Financials

$40.00

$0.00 (0.00%)

As on 27-Sep-2024 09:30EDT

Market cap

$1,097 Mln

Revenue (TTM)

$1,601 Mln

P/E Ratio

--

P/B Ratio

103.1

Div. Yield

0 %

Annual
Quarterly

Income Statement (kr Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Operating Revenue	1,601.41	1,206.89	802.88	229.35	0.87	184.83
Cost of Revenue	104.68	77.06	15.20	--	--	--
Gross Profit	1,496.73	1,129.83	787.68	229.35	0.87	184.83
Operating Expenses	1,864.91	1,514.23	1,209.62	753.80	383.10	212.71
Operating Profit (EBIT)	-368.18	-384.40	-421.94	-524.46	-379.72	-28.02
Other Income	--	--	--	--	--	--
Profit before Tax	-468.32	-457.02	-409.42	-513.37	-436.15	-32.50
Provision for Tax	12.04	9.17	2.85	-3.84	0.36	0.08
Profit after Tax (Net Income)	-480.36	-466.19	-412.27	-509.54	-436.51	-32.58
Minority Interest	--	--	-0.50	9.24	45.81	45.81
Consolidated Profit	-168.36	--	-412.27	-500.29	-433.49	-32.58

Liabilities (kr Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Shareholder's Funds	106.79	334.81	766.26	1,008.28	1,210.49	788.07
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	1,210.64	1,158.60	861.48	316.18	144.53	3.76
Current Liabilities	429.78	407.14	325.23	135.45	105.62	53.37
Total Liabilities	2,176.98	1,900.55	1,952.97	1,459.91	1,506.45	845.20

Assets (kr Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Non-Current Assets	592.74	625.40	540.77	447.14	469.60	24.07
Current Assets	1,154.46	1,275.15	1,412.20	1,012.77	1,036.85	821.13
Total Assets	2,176.98	1,900.55	1,952.97	1,459.91	1,506.45	845.20
Total Debt*	1,008.27	979.13	728.82	213.22	4.79	6.07
Net Current Assets	724.69	868.01	1,086.97	877.33	931.23	767.76

Cashflow (kr Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Cash From Operating Activities	--	-434.66	-311.35	-461.59	-309.18	-71.01
Cash Flow from Investing Activities	--	-13.75	-5.14	-24.34	-172.61	-18.07
Cash from Financing Activities	--	199.65	575.99	435.16	768.56	198.84
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Adjusted EPS (kr)	-17.56	-8.69	-15.48	-19.47	-17.48	-1.68
Cash EPS (kr)	--	-7.78	-15.00	-18.15	-17.37	-1.59
Adjusted Book Value (kr)	--	6.24	28.77	38.53	48.48	40.72
Dividend per Share (kr)	--	--	--	--	--	--
Cash Flow per Share (kr)	--	-8.10	-11.69	-17.64	-12.38	-3.67
Free Cash Flow per Share (kr)	--	-8.34	-11.79	-18.50	-12.38	-4.51

Profitability Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
ROCE (%)	--	-33.19	-30.35	-41.82	-43.45	-4.61
ROE (%)	-217.56	-84.68	-46.46	-45.93	-43.68	-4.63
ROA (%)	-23.00	-24.20	-24.16	-34.35	-37.12	-4.36
EBIT Margin (%)	-23.02	-31.85	-52.55	-226.02	-43,732.38	-14.58
Net Margin (%)	-30.00	-38.63	-51.35	-222.17	-49,944.05	-17.63
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Revenue Growth (%)	39.27	0.50	2.50	261.41	-1.00	--
EBIT Growth (%)	-71.35	8.90	18.60	-35.62	-1,318.15	79.76
Net Profit Growth (%)	-64.37	-13.08	19.09	-16.73	-1,239.90	75.33
EPS Growth (%)	-56.24	0.44	0.20	-0.11	-9.38	0.78
Book Value Growth (%)	-78.83	--	--	--	--	--

Solvency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debt to Equity	9.20	2.92	0.95	0.21	0.00	0.01
Short term debt to equity ratio	--	0.04	0.01	0.05	0.00	0.00
Current Ratio	2.69	3.13	4.34	7.48	9.82	15.39
Quick Ratio	2.59	3.08	4.33	7.47	9.82	15.04
Interest Coverage	-3.07	-5.25	-33.69	-72.93	-972.57	-82.93

Operating Efficiency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debtors to sales (%)	13.90	15.59	10.09	24.58	2,030.43	25.20
Asset Turnover	0.77	0.63	0.47	0.15	0.00	0.25
Receivable days	--	40.73	31.25	59.02	13,442.37	92.06
Inventory Days	--	57.06	54.50	--	--	--
Payable days	--	618.49	2,743.70	--	--	--
Cash Conversion Cycle	--	-520.70	-2,657.96	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.